RxDoctor Payments Data

Camille Hylton, MD

Ophthalmology · Tempe, AZNPI 1629019732

Payments from drug & device makers

$2,237in general payments, 2019–2025

Across 89 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$447
  • Notal Vision, Inc.$402
  • Alcon$242
  • Sun Pharmaceutical Industries Inc.$174
  • Bausch & Lomb Americas Inc.$155
  • Aerie Pharmaceuticals, Inc.$137
  • plus $679 from 15 others

What the payments were for

  • Speaking & faculty fees$40218%
  • Food & beverage$1,73778%
  • Education$984%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,237 in reported general payments places this provider in the 55th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$328,687
Medicare patients
874
Services billed
3,340

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost323$178,522
RhopressaNetarsudil Mesylate160$72,638
CombiganBrimonidine Tartrate/Timolol122$63,677
VyzultaLatanoprostene Bunod120$48,692
RocklatanNetarsudil Mesylat/Latanoprost92$46,513
RestasisCyclosporine43$41,036
Alphagan PBrimonidine Tartrate64$31,269
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol144$26,997
Brimonidine Tartrate510$22,412
Latanoprost1,357$16,487
SimbrinzaBrinzolamide/Brimonidine Tart45$15,630
Brinzolamide75$15,531
Travoprost78$14,314
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat547$12,484
Cyclosporine20$10,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$447$314,505552 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$137$119,151252 claims
Bausch & Lomb Americas Inc.Vyzulta$155$48,692120 claims
AlconSimbrinza$242$15,63045 claims
Thea Pharma Inc.Iyuzeh$76$3,80011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 310 ophthalmology providers in Arizona.

Other ophthalmology in Tempe

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →